Latest Regulatory Approvals News

VIP Gloves Limited has obtained a short-term interest-free loan of approximately AUD$1 million ahead of a planned share placement, as it faces potential delisting from the ASX pending a critical reinstatement decision.

PYC Therapeutics has secured regulatory approval to initiate human trials of PYC-003, a novel drug candidate targeting the root cause of Polycystic Kidney Disease (PKD). Initial safety and efficacy data are expected within 2025, marking a critical step in addressing a disease affecting millions worldwide.

Radiopharm Theranostics' RAD 101 radiotracer demonstrates high sensitivity in detecting brain metastases using a novel PET-mpMRI approach, with a Phase 2b trial now recruiting in the US.

Black Dragon Gold has applied for its Salave Gold Project to be designated a Strategic Investment Project under new regional legislation in Asturias, aiming to fast-track development and boost local economic benefits.

Moho Resources has agreed to sell its Empress Springs Project in Western Queensland for $1.258 million, including deferred payments and a retained royalty, as it refocuses its portfolio.

DMC Mining Limited has extended the closing date for its public share offer to May 8, 2025, due to delays in obtaining exploration licenses for its Firawa and Labe Projects in Guinea. The company plans to lodge a second supplementary prospectus to adjust regulatory conditions accordingly.

Neuren Pharmaceuticals has received a significant cash inflow of approximately US$50 million following the sale of a Priority Review Voucher linked to its Rett syndrome treatment. This milestone underscores the growing value of Neuren’s neurological drug portfolio and its partnership with Acadia Pharmaceuticals.

Australian Rare Earths Limited has launched a significant 2025 drilling campaign at its Overland Uranium Project, targeting promising palaeovalley structures and high-priority zones following encouraging 2024 results. Regulatory approvals for the Sheer Gold Farm-In further expand exploration potential.

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

News Corporation reported a robust half-year performance with revenues up 4% to $4.33 billion and net income soaring 80% to $334 million, while advancing its strategic pivot through the planned sale of Foxtel.

Polymetals Resources Ltd has temporarily paused trading of its securities, signaling an imminent announcement that could reshape investor expectations.

Micro-X Ltd has announced a $6 million capital raising alongside a $2.4 million strategic investment from Billion Prima, underpinning its pivot towards medical imaging and cashflow stability.